Biotech Values

[DewDiligence]

DVAX seeks to challenge Shingrix:

https://www.prnewswire.com/news-releases/dynavax-initiates-phase-12-study-of-novel-shingles-vaccine-program-302185089.html

Dynavax Technologies Corporation…today announced that the first participant has been dosed in a Phase 1/2 clinical trial evaluating the safety, tolerability, and immunogenicity of Z-1018, the company's investigational vaccine candidate being developed for the prevention of shingles…

“We believe there is an opportunity to develop an improved shingles vaccine with a significantly better tolerability profile compared to the market-leading shingles vaccine. One of the unique advantages of our vaccine candidate is CpG 1018 adjuvant's established safety and tolerability profile…,” said Rob Janssen,…Chief Medical Officer of Dynavax.

DVAX has a long way to go to catch Shingrix, but DVAX has solid credibility in the vaccine arena from the development and commercialization of Heplisav-B for HBV.